1986: title of model worker in health system, published the paper "HBV Infection Aggregation in Family Members of Patients with Liver Cancer" and won the National Youth Paper Excellence Award (HBV Infection Aggregation in Family Members of Patients with Liver Cancer).
1999: Top Ten News Figures of China People.
2000: China Excellent Science and Technology Essays.
200 1: People's Republic of China (PRC) and the State Council authorized the State Administration of Foreign Experts Affairs to establish the National Friendship Award.
200 1: China Medical Science and Technology Award (International Science and Technology Cooperation Award).
2065438+02: "Loyalty Award" issued by ITPC.
Published papers 100. Leadership meeting
Take the lead in convening high-level working meetings of major pharmaceutical companies (Merck, Glaxo Wellcome, Roche, Bristol-Myers Squibb, etc.). ) attended by leaders at all levels of the Ministry of Health and famous Chinese-American AIDS experts Professor He Dayi and Professor sculli, which laid a policy foundation for the smooth development of AIDS clinical treatment in China.
Clinical trial therapy
We cooperated with Merck, Glaxo Wellcome and Bristol-Myers Squibb for three clinical trials, and the results were very satisfactory. She used her good relationship with foreign pharmaceutical companies and various foundations to win a lot of funding for AIDS prevention and treatment in China. Since July 1998, she has applied to major pharmaceutical companies in the United States for AIDS drugs worth nearly 100 dollars for free use by patients. At the same time, she also received $500,000 from major pharmaceutical companies and foundations for experimental research on clinical treatment, and 2 million yuan was directly used nationwide. The clinical treatment of highly effective retrovirus has been started and popularized throughout the country. Among them, 74 AIDS patients in three clinical treatment groups received free drugs from major pharmaceutical companies in the United States, Britain and Germany. The analysis of treatment effect was published as a paper report at the Asia-Pacific Conference (Malaysia) and the Seventh Retrovirus Conference (San Francisco, USA), the 13 International AIDS Conference held in South Africa and the first World Congress on the Pathogenesis and Treatment of AIDS held in Argentina. The treatment summary has been written into three papers.
At the same time, she has been exploring the promotion of "the best drug treatment scheme" in China. In view of the problem that China has a vast territory and the distribution of AIDS-infected people is not concentrated, she has set up clinical treatment points in key cities of AIDS infection in China. I believe this will have a far-reaching impact on the prevention and treatment of AIDS in China, hoping to make people realize that AIDS is a "chronic disease in the world" and stop talking about the color change of AIDS, and also hope to bring positive influence to the government.
Exploration and recognition of traditional Chinese medicine treatment
Actively carry out effective Chinese medicine treatment, evaluate the curative effect with strict scientific indicators, and strive for joint use with western medicine. 50 cases in 7 clinical treatment groups of traditional Chinese medicine were carried out, and the standardized standard of curative effect of traditional Chinese medicine on AIDS was drafted for WHO.
Guidance and training on AIDS prevention and treatment in China.
Guidance and training for the prevention and treatment of AIDS in the whole country Strengthen the training and guidance for clinicians and inspectors in all provinces and cities throughout the country, and popularize anti-AIDS treatment throughout the country. It can be said that the implementation of this project has brought the greatest benefits to HIV-infected people and patients in China. Judging from the long-term goal of AIDS prevention and control in China, it will fundamentally reduce the source of infection. Thanks to highly effective antiretroviral therapy (HAART) in developed countries such as Europe and America, the infection rate, morbidity and mortality of AIDS have obviously decreased. I believe that the adoption of HAART in China will also improve the rising trend of AIDS, which will play a great role in reducing the pressure on the government in this regard and lay a foundation for future treatment, prevention and vaccine evaluation. At present, standardized and efficient antiretroviral therapy (HAART) has been carried out nationwide. Through study and further research, many hospitals in many provinces have begun to treat patients, and the treatment of AIDS has been in line with international standards. It can be said that the implementation of this project has brought the greatest benefits to HIV-infected people and patients in China. Judging from the long-term goal of preventing and treating AIDS in China, it will fundamentally reduce the source of infection.
Drug prevention and treatment of mother-to-child block
Blocking the mother-to-child transmission of HIV, children suffering from AIDS has become a noticeable social problem in the world. However, there is no comprehensive and systematic retrospective investigation and no forward-looking detection and monitoring scheme in China. As a member of the World Committee on Mother-to-Child Transmission of AIDS, Professor Cao deeply felt the necessity of blocking mother-to-child transmission of AIDS in China. To this end, she cooperated with foreign pharmaceutical companies to carry out the "Study on Blocking Mother-to-Child Transmission of HIV in China". The therapeutic drugs have reached agreements with Glaxo Wellcome Pharmaceutical Co., Ltd. and Boehringer Ingelheim Company. In Yunnan and Xinjiang, the drug prevention and treatment of mother-to-child block began.
Detection of HIV antibody in urine
Introduce and popularize the latest international non-invasive diagnosis technology of HIV-urine HIV antibody detection in China. Professor Cao Yunzhen was invited by the Medical Center of new york University in the United States as a visiting professor to engage in AIDS research in 1986. In the same year, in 12, she first found HIV- 1 antibody in the urine of HIV-infected people and AIDS patients. After two years of repeated research and confirmation, it has been unanimously recognized by the academic community. And obtained medical patents in 17 countries including the United States in 1998. On July 1998, Professor Cao Yunzhen reported to work in Beijing the next day without any rest, and proposed to introduce the urine HIV antibody diagnosis and detection technology. After one year's efforts, Ai Hua Company of AIDS Prevention and Control Center of Ministry of Health has obtained the distribution right of reagents, and has started negotiations with American companies to establish a joint venture factory to produce reagents in China, which can greatly reduce the cost of urine reagents and spread them to the third world. China is a multi-ethnic country, and the high-incidence areas of AIDS are mainly ethnic minorities in the western region. 70.6% of AIDS infection sources are due to intravenous drug use. Therefore, the collection of blood samples is a big problem in the prevention and treatment of AIDS. The development of urine testing for AIDS has achieved non-invasive testing, which has solved this problem well and made better measures for AIDS screening, which is conducive to the early detection of AIDS-infected people. Professor Cao introduced urine test reagents to China. Ai Hua Company of Wei 'ai Center has not only obtained the distribution right of reagents, but also started to negotiate with American companies to establish a joint venture factory, so that China can manufacture reagents by itself, which can greatly reduce the price of HIV antibody reagents for urine test, and can also be extended to the third world, which is conducive to the prevention and treatment of AIDS in the world.